Prevention and treatment options for mTOR inhibitor-associated stomatitis

  title={Prevention and treatment options for mTOR inhibitor-associated stomatitis},
  author={Kelly Staves and Kavitha Ramchandran},
  journal={The Journal of community and supportive oncology},
Mammalian target of rapamycin (mTOR), a serine–threonine protein kinase, operates in the phosphoinositide 3-kinase (PI3K)–protein kinase B (AKT)–mTOR signal transduction pathway regulating both normal and cancer cellular processes, including cell growth, proliferation, motility, survival, and protein and lipid synthesis.1 Genetic alterations affecting this pathway, including mutations in receptor tyrosine kinases PI3K and AKT, occur frequently in human cancers,2 supporting the rationale to… 

Figures and Tables from this paper

Prevention of Stomatitis

Recommendations are provided for oncology nurses to educate patients on prevention, early detection, monitoring, and management strategies to mitigate the incidence and severity of everolimus‐related stomatitis.



The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.

The role of the PI3-kinase-Akt-mTOR pathway in breast cancer biology and the clinical trial evidence available to date are reviewed.

PI3K and cancer: lessons, challenges and opportunities

Through a greater focus on patient selection, increased understanding of immune modulation and strategic application of rational combinations, it should be possible to realize the potential of this promising class of targeted anticancer agents.

Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors.

The severity of mIAS can be minimized by following common preventive steps and initiating treatment at the first sign of mouth discomfort, thereby reducing the likelihood of treatment discontinuation.

MicroRNA-99 Family Targets AKT/mTOR Signaling Pathway in Dermal Wound Healing

Evidence that miR-99 family members contribute to wound healing by regulating the AKT/mTOR signaling is provided.

Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients

An analysis of the appearance, course, and toxicity associations of mTOR inhibitor‐associated stomatitis (mIAS) demonstrated that the condition is distinct from conventional mucositis (CM) and more closely resembles aphthous stom atitis.

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

  • A. O’DonnellS. Faivre I. Judson
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
Everolimus was satisfactorily tolerated at dosages up to 70 mg/wk and 10 mg/d with predictable PK and Antitumor activity and PD in tumors require further clinical investigation.

Periostin Responds to Mechanical Stress and Tension by Activating the MTOR Signaling Pathway

These findings identify Periostin as a mechanical stress responsive molecule that is primarily secreted by fibroblasts during wound healing and expressed endogenously in epithelial cells resulting in the control of cellular physiology through a mechanism mediated by the mTOR signaling cascade.